UPClytics
ENDE
Sign inStart trial
View all cases

UPC CFI 124/2024

Mar 19, 2024·EP3167888 Unitary patent · TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Follow
Case details
Status
Case Closed
Action
Provisional measures
Category
Provisional measures
Parties
Claimants
Representatives
Respondents
Representatives
Division
Hamburg LD
Judges
Technology
  • Chemistry
    Biotechnology · Pharmaceuticals
Language
English
First decided
Jun 26, 2024
EPO Opposition
How this compares
The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.
Preliminary injunction grantedMedian days to first decision
All UPC54% (38/70)124
Hamburg LDLockedLocked
Judge Sabine KlepschLockedLocked
Judge Alima ZanaLockedLocked
Judge Stefan SchillingLockedLocked
Judge Rudi GoedeweeckLockedLocked

At the UPC: AstraZeneca Group (13 cases)·Amgen Group (19 cases)

Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patent

This dispute contains 2 other proceedings

UPC APP 43687/2024·UPC CoA 405/2024

6 other defendants litigating the same or a related patent

UPC CoA 744/2025·UPC CFI 674/2025·UPC CFI 51/2025·UPC CFI 642/2024·UPC CoA 402/2024 and 1 more

Start a free trial to see how each one ended.

More cases: Hamburg LD·2024

Decisions
  • 2024-06-26
    Application for provisional measuresPublic

    Summary: The Hamburg Local Division dismissed Alexion Pharmaceuticals' application for a preliminary injunction against multiple Amgen entities based on EP 3 167 888, holding that while infringement could be established the court lacked sufficient certainty of patent validity given the EPO's repeated rejection of sequence correction attempts for SEQ ID NO:4.

    Show the legal issues (3)
    • preliminary injunction standard Art. 62(2) UPCA
    • validity certainty requirement Art. 62(4) UPCA
    • SEQ ID NO:4 disclosure and correction history
Documents
Document titleDatePublic
Case closed2025-12-05Not public
Order2025-12-05Not public
Order2025-12-05Not public
Cover sheet2025-12-03Not public
Other document Defendant2025-12-03Not public
Other document Defendant2025-12-03Not public
Receipt2025-12-03Not public
Order2025-12-02Not public
Order2025-12-02Not public
Cover sheet2025-11-26Not public
Other document Claimant2025-11-26Not public
Receipt2025-11-26Not public
Comments2025-09-18Not public
Outcome of the Order2025-09-10Not public
deadline extension2025-09-10Public
Receipt2025-09-10Not public
Receipt2025-09-10Not public
262.2 Application2025-09-09Not public
Deadline extension request2025-09-09Not public
Deadline extension request2025-09-09Not public
anonymisierte Version2025-09-04Not public
anonymisierte Version2025-09-04Not public
Anhoerung2025-08-26Not public
Template-Order2025-08-26Not public
Outcome of the Order2025-08-25Not public
Order with grounds2025-08-25Public
Receipt2025-08-20Not public
20250820_Application_for_rectification_Amgen_EN signiert2025-08-20Not public
Receipt2025-08-20Not public
Receipt2025-08-20Not public
Receipt2025-08-20Not public
Receipt2025-08-20Not public
Receipt2025-08-20Not public
Receipt2025-08-20Not public
Receipt2025-08-20Not public
Application_262_2_RoP_Costs_Rehearing_Amgen_33361_2025 signed2025-08-19Not public
Application_262_2_RoP_Costs_Appeal_Proceedings_Amgen_3053_2025 signed2025-08-19Not public
Application_262_2_RoP_Costs_First_Instance_Amgen_43687_2024 signed2025-08-19Not public
2025-07-21 Rehearing - Application for cost decision - Amgen - signed - confidential2025-08-19Not public
Request_9_1_RoP_Costs_Rehearing_Amgen_33361_2025_35088_2025 signed2025-08-19Not public
2025-07-21 Rehearing - Application for cost decision - Amgen - signed - confidential2025-08-19Not public
2025-01-20 Second Instance - Application for cost decision - Amgen - signed - confidential2025-08-19Not public
2025-01-20 Second Instance - Application for cost decision - Amgen - signed - confidential2025-08-19Not public
Request_9_1_RoP_Costs_Appeal_Proceedings_Amgen_3053_2025_35087_2025 signed2025-08-19Not public
2024-07-26 First Instance - Application for cost decision - Amgen - signed - confidential2025-08-19Not public
2024-07-26 First Instance - Application for cost decision - Amgen - signed - confidential2025-08-19Not public
Request_9_1_RoP_Costs_First_Instance_Amgen_43687_2025_35086_2025 signed2025-08-19Not public
2025-07-14 First Instance - Reply of Amgen - 43687_2024 - signed - confidential2025-08-19Not public
2025-07-14 First Instance - Reply of Amgen - 43687_2024 - signed - confidential2025-08-19Not public
Comments on application for rehearing costs2025-08-19Not public
262a2025-08-05Not public
262a2025-08-05Not public
262a2025-08-05Not public
262A2025-08-05Not public
Anhoerung2025-08-05Not public
Outcome of the Order2025-08-05Not public
Order with grounds2025-08-05Not public
Order with grounds2025-08-05Public
Order with grounds2025-08-05Public
Order with grounds2025-08-05Not public
Comments2025-08-04Not public
Anhoerung2025-07-28Not public
Receipt2025-07-22Not public
Receipt2025-07-22Not public
Confidentiality_Request_re_Application_cost_decision_rehearing_EN2025-07-21Not public
Confidentiality_Request_re_Application_cost_decision_rehearing_EN2025-07-21Not public
Application_cost_decision_rehearing_Confidential_EN2025-07-21Not public
Application_cost_decision_rehearing_Confidential_EN2025-07-21Not public
Outcome of the Order2024-09-30Not public
Confirmation of appointment – oral hearing recording2024-09-30Public
Receipt2024-09-26Not public
Request to the Registrar for the recording of the oral hearing to be made available2024-09-25Not public
Order with grounds (ORD_38132_2024)2024-07-17Not public
Measures_DecisionOutcome_Notification.pdf2024-06-26Not public
procedural order2024-06-26Public
Recording2024-06-26Not public
Recording2024-06-26Not public
summons2024-06-25Not public
closing written proceedings2024-06-25Public
Closing workflow2024-06-18Public
Comments2024-06-14Not public
Exhibit FBD 38a2024-06-14Not public
Exhibit_BP202024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP232024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP222024-06-14Not public
Exhibit_BP242024-06-14Not public
Exhibit_BP182024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP272024-06-14Not public
Exhibit_BP282024-06-14Not public
Exhibit_BP252024-06-14Not public
Exhibit_BP172024-06-14Not public
Exhibit_BP192024-06-14Not public
Exhibit_BP212024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP262024-06-14Not public
Exhibit_BP242024-06-14Not public
Exhibit_BP272024-06-14Not public
Exhibit_BP202024-06-14Not public
Exhibit_BP182024-06-14Not public
Exhibit_BP232024-06-14Not public
Exhibit_BP192024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP172024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP262024-06-14Not public
Exhibit_BP252024-06-14Not public
Exhibit_BP212024-06-14Not public
Exhibit_BP282024-06-14Not public
Exhibit_BP222024-06-14Not public
Exhibit_BP182024-06-14Not public
Exhibit_BP222024-06-14Not public
Exhibit_BP252024-06-14Not public
Exhibit_BP172024-06-14Not public
Exhibit_BP212024-06-14Not public
Exhibit_BP192024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP282024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP232024-06-14Not public
Exhibit_BP202024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP262024-06-14Not public
Exhibit_BP242024-06-14Not public
Exhibit_BP272024-06-14Not public
Exhibit_BP212024-06-14Not public
Exhibit_BP272024-06-14Not public
Exhibit_BP202024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP232024-06-14Not public
Exhibit_BP282024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP262024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP242024-06-14Not public
Exhibit_BP172024-06-14Not public
Exhibit_BP222024-06-14Not public
Exhibit_BP252024-06-14Not public
Exhibit_BP182024-06-14Not public
Exhibit_BP192024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP212024-06-14Not public
Exhibit_BP202024-06-14Not public
Exhibit_BP262024-06-14Not public
Exhibit_BP272024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP242024-06-14Not public
Exhibit_BP192024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP172024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP282024-06-14Not public
Exhibit_BP252024-06-14Not public
Exhibit_BP182024-06-14Not public
Exhibit_BP222024-06-14Not public
Exhibit_BP232024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP182024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP242024-06-14Not public
Exhibit_BP212024-06-14Not public
Exhibit_BP252024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP282024-06-14Not public
Exhibit_BP232024-06-14Not public
Exhibit_BP172024-06-14Not public
Exhibit_BP272024-06-14Not public
Exhibit_BP262024-06-14Not public
Exhibit_BP192024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP222024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP202024-06-14Not public
Exhibit_BP262024-06-14Not public
Exhibit_BP212024-06-14Not public
Exhibit_BP192024-06-14Not public
Exhibit_BP182024-06-14Not public
Exhibit_BP242024-06-14Not public
Exhibit_BP272024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP252024-06-14Not public
Exhibit_BP282024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP232024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP222024-06-14Not public
Exhibit_BP172024-06-14Not public
Exhibit_BP202024-06-14Not public
Exhibit_BP262024-06-14Not public
Exhibit_BP242024-06-14Not public
Exhibit_BP192024-06-14Not public
Exhibit_BP182024-06-14Not public
Exhibit_BP272024-06-14Not public
Exhibit_BP232024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP252024-06-14Not public
Exhibit_BP282024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP172024-06-14Not public
Exhibit_BP202024-06-14Not public
Exhibit_BP212024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP222024-06-14Not public
Exhibit_BP252024-06-14Not public
Exhibit_BP222024-06-14Not public
Exhibit_BP212024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP262024-06-14Not public
Exhibit_BP172024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP232024-06-14Not public
Exhibit_BP242024-06-14Not public
Exhibit_BP29 - confidential2024-06-14Not public
Exhibit_BP182024-06-14Not public
Exhibit_BP272024-06-14Not public
Rejoinder_of_Amgen_CONFIDENTIAL_EN_signed2024-06-14Not public
Exhibit_BP192024-06-14Not public
Exhibit_BP282024-06-14Not public
Exhibit_BP202024-06-14Not public
Vorlage Skerra2024-06-14Not public
Outcome of the Order2024-05-28Not public
Deadline amgen2024-05-28Public
Receipt2024-05-28Not public
Application/Submission2024-05-27Not public
Outcome of the Order2024-05-24Not public
Closing workflow2024-05-24Public
Duplik Defendant2024-05-24Not public
Receipt2024-05-24Not public
R 262 Application2024-05-24Not public
Exhibit FBD 562024-05-24Not public
Exhibit FBD 632024-05-24Not public
Exhibit FBD 612024-05-24Not public
Exhibit FBD 522024-05-24Not public
Exhibit FBD 542024-05-24Not public
Part I of the Reply2024-05-24Not public
Exhibit FBD 432024-05-24Not public
Exhibit FBD 472024-05-24Not public
Exhibit FBD 512024-05-24Not public
Exhibit FBD 532024-05-24Not public
Part II of the Reply2024-05-24Not public
Exhibit FBD 372024-05-24Not public
Exhibit FBD 552024-05-24Not public
Exhibit FBD 572024-05-24Not public
Exhibit FBD 402024-05-24Not public
Exhibit FBD 492024-05-24Not public
Exhibit FBD-A 22024-05-24Not public
Part II of the Reply2024-05-24Not public
Exhibit FBD 382024-05-24Not public
Exhibit FBD 662024-05-24Not public
Exhibit FBD 642024-05-24Not public
Exhibit FBD 412024-05-24Not public
Exhibit FBD 422024-05-24Not public
Exhibit FBD 622024-05-24Not public
Exhibit FBD 462024-05-24Not public
Exhibit FBD 652024-05-24Not public
Exhibit FBD 602024-05-24Not public
Exhibit FBD 352024-05-24Not public
Exhibit FBD 592024-05-24Not public
Exhibit FBD 452024-05-24Not public
Exhibit FBD 672024-05-24Not public
Exhibit FBD 482024-05-24Not public
Exhibit FBD 502024-05-24Not public
Exhibit FBD-A 12024-05-24Not public
Exhibit FBD 362024-05-24Not public
Exhibit FBD 582024-05-24Not public
Exhibit FBD 442024-05-24Not public
Exhibit FBD 662024-05-24Not public
Exhibit FBD 392024-05-24Not public
Outcome of the Order2024-05-16Not public
Frist2024-05-16Public
Receipt2024-05-16Not public
Anlage FBD FV 12024-05-16Not public
Rule 9.3 Extension request2024-05-16Not public
Anlage FBD FV 22024-05-16Not public
Outcome of the Order2024-05-07Not public
Frist applicant2024-05-07Public
summon to oral hearing2024-05-03Not public
Receipt2024-05-02Not public
Exhibit_BP10_Amgen_Related_proceedings_confidential_en2024-04-30Not public
Exhibit_BP09h_Amgen_en2024-04-30Not public
Exhibit_BP14_Amgen_en2024-04-30Not public
Exhibit_BP10e_Amgen_confidential_nl2024-04-30Not public
Exhibit_BP09f_Amgen_en2024-04-30Not public
Objection_Amgen_dd_April_30_2024_Confidential_en_signed2024-04-30Not public
Exhibit_BP09b_Amgen_en2024-04-30Not public
Exhibit_BP12_Amgen_en2024-04-30Not public
Exhibit_BP15_Amgen_en2024-04-30Not public
Exhibit_BP09c_Amgen_en2024-04-30Not public
Exhibit_BP00_Amgen_en_signed2024-04-30Not public
Exhibit_BP04_Amgen_Confidential_en2024-04-30Not public
Exhibit_BP09d_Amgen_en2024-04-30Not public
Exhibit_BP09m_Amgen_en2024-04-30Not public
Exhibit_BP09i_Amgen_en2024-04-30Not public
Exhibit_BP07_Amgen_en2024-04-30Not public
Exhibit_BP08_Amgen_Table_Grant_procedures_en2024-04-30Not public
Exhibit_BP10e_Amgen_confidential_nl2024-04-30Not public
Exhibit_BP02_Amgen_en2024-04-30Not public
Exhibit_BP10a_Amgen_confidential_de2024-04-30Not public
Exhibit_BP10_Amgen_Related_proceedings_confidential_en2024-04-30Not public
Exhibit_BP09n_Amgen_en2024-04-30Not public
Exhibit_BP10b_Amgen_confidential_en2024-04-30Not public
Exhibit_BP10d_Amgen_confidential_en2024-04-30Not public
Exhibit_BP10c_Amgen_confidential_en2024-04-30Not public
Exhibit_BP10c_Amgen_confidential_en2024-04-30Not public
Exhibit_BP09l_Amgen_en2024-04-30Not public
Exhibit_BP09a_Amgen_en2024-04-30Not public
Exhibit_BP03_Amgen_Technical_background_en2024-04-30Not public
Exhibit_BP01_Amgen_en2024-04-30Not public
Exhibit_BP10d_Amgen_confidential_en2024-04-30Not public
Exhibit_BP13_Amgen_en2024-04-30Not public
Exhibit_BP06_Amgen_en2024-04-30Not public
Exhibit_BP09p_Amgen_en2024-04-30Not public
Exhibit_BP09j_Amgen_en2024-04-30Not public
Exhibit_BP05_Amgen_en2024-04-30Not public
Exhibit_BP09g_Amgen_en2024-04-30Not public
Exhibit_BP11_Amgen_file_wrapper_estoppel_en2024-04-30Not public
Exhibit_BP09o_Amgen_en2024-04-30Not public
Exhibit_BP04_Amgen_Confidential_en2024-04-30Not public
Exhibit_BP09e_Amgen_en2024-04-30Not public
Exhibit_BP16_Amgen_en2024-04-30Not public
Exhibit_BP09_Amgen_Grant_history_en2024-04-30Not public
Objection_Amgen_dd_April_30_2024_Confidential_en_signed2024-04-30Not public
Exhibit_BP10a_Amgen_confidential_de2024-04-30Not public
Exhibit_BP10b_Amgen_confidential_en2024-04-30Not public
Exhibit_BP09k_Amgen_en2024-04-30Not public
Panel-Appointment2024-04-17Not public
Procedural Order2024-04-14Not public
Template-Order2024-04-14Not public
Receipt2024-04-09Not public
Antrag/Schriftsatz2024-04-09Not public
Notification Of Service2024-04-09Not public
Mail Service Sweden2024-04-09Not public
Acknowledgement of access to case2024-04-09Not public
Acknowledgement of access to case2024-04-02Not public
Acknowledgement of access to case2024-04-02Not public
Acknowledgement of access to case2024-04-02Not public
Acknowledgement of access to case2024-04-02Not public
Acknowledgement of access to case2024-04-02Not public
Acknowledgement of access to case2024-04-02Not public
Acknowledgement of access to case2024-04-02Not public
Acknowledgement of access to case2024-04-02Not public
Notification Of Service2024-03-28Not public
Service Italy2024-03-28Not public
Service Italien2024-03-28Not public
Notification Of Service2024-03-28Not public
Service French2024-03-28Not public
Service Frankreich2024-03-28Not public
Notification Of Service2024-03-27Not public
Service Portugal2024-03-27Not public
Notification Of Service2024-03-27Not public
Service Belgium2024-03-27Not public
Notification Of Service2024-03-27Not public
Service Munich2024-03-27Not public
Notification Of Service2024-03-26Not public
Service Ireland2024-03-26Not public
Panel-Appointment2024-03-26Not public
Notification Of Service2024-03-26Not public
Service Slovenia2024-03-26Not public
Notification Of Service2024-03-26Not public
Service Austria2024-03-26Not public
Invitation to lodge2024-03-20Public
Letter for Service2024-03-20Not public
Letter for Service2024-03-20Not public
Letter for Service2024-03-20Not public
Letter for Service2024-03-20Not public
Letter for Service2024-03-20Not public
Letter for Service2024-03-20Not public
Letter for Service2024-03-20Not public
Letter for Service2024-03-20Not public
Letter for Service2024-03-20Not public
Receipt2024-03-20Not public
Application to request confidentiality from the public2024-03-19Not public
Panel-Appointment2024-03-19Not public
Application-For-Measures-Receipt2024-03-19Not public
Formal-checks_Notification-of-positive-outcome2024-03-19Not public
Application-For-Measures-Acknowledgement2024-03-19Not public
Exhibit FBD 17a2024-03-19Not public
Exhibit FBD 42024-03-19Not public
Confidential Exhibit FBD 22024-03-19Not public
Application for Provisional Measures2024-03-19Not public
Exhibit FBD 18a2024-03-19Not public
Exhibit FBD 152024-03-19Not public
Exhibit FBD 272024-03-19Not public
Exhibit FBD 162024-03-19Not public
Confidential Exhibit FBD 22024-03-19Not public
Set of Exhibits FBD 5b2024-03-19Not public
Set of Exhibits FBD 5a2024-03-19Not public
Exhibit FBD 282024-03-19Not public
Exhibit FBD 182024-03-19Not public
Exhibit FBD 17b2024-03-19Not public
Exhibit FBD 32024-03-19Not public
Exhibit FBD 292024-03-19Not public
Exhibit FBD 33a2024-03-19Not public
Exhibit FBD 262024-03-19Not public
Exhibit FBD 112024-03-19Not public
Exhibit FBD 72024-03-19Not public
Exhibit FBD 122024-03-19Not public
Exhibit FBD 92024-03-19Not public
Exhibit FBD 62024-03-19Not public
Exhibit FBD 17c2024-03-19Not public
Exhibit FBD 252024-03-19Not public
Exhibit FBD 212024-03-19Not public
Exhibit FBD 102024-03-19Not public
Exhibit FBD 12024-03-19Not public
Exhibit FBD 82024-03-19Not public
Exhibit FBD 232024-03-19Not public
Application for Provisional Measures2024-03-19Not public
Exhibit FBD 142024-03-19Not public
Exhibit FBD 312024-03-19Not public
Exhibit FBD 322024-03-19Not public
Exhibit FBD 342024-03-19Not public
Exhibit FBD 02024-03-19Not public
Exhibit FBD 242024-03-19Not public
Exhibit FBD 302024-03-19Not public
Exhibit FBD 202024-03-19Not public
Exhibit FBD 222024-03-19Not public
Exhibit FBD 192024-03-19Not public
Exhibit FBD 332024-03-19Not public
Exhibit FBD 132024-03-19Not public
Exhibit FBD 32a2024-03-19Not public
Plain-English summary

Alexion Pharmaceuticals applied for a preliminary injunction at the Hamburg Local Division against nine Amgen entities across multiple European countries regarding EP 3 167 888 B1 (eculizumab/paroxysmal nocturnal haemoglobinuria). Identical reasoning to UPC_CFI_123/2024: the court found infringement could be established but denied the measure because the TBA's consistent rejection of SEQ ID NO:4 correction attempts created insufficient certainty of patent validity; value of dispute was EUR 100,000,000.

Accepted arguments
What the court agreed with — by party.

  • Sufficient certainty of patent validity is required before granting provisional measures, assessed in light of likely EPO outcome

    RespondentLegal basis: Art. 62(4) UPCA; R. 211.2 RoP

    Note: Same legal reasoning as UPC_CFI_123/2024: the Hamburg court declined the PI because TBA history created serious doubt about EP 3 167 888 B1's validity.

Rejected arguments
What the court did not agree with — and why.

  • Preliminary injunction against Amgen entities based on EP 3 167 888 B1

    ClaimantLegal basis: Art. 62(4) UPCA; R. 211.2 RoP

    Reason: Although infringement could be established, the court lacked sufficient certainty of patent validity given the TBA's consistent rejection of all attempts to correct SEQ ID NO:4 and claim sets directed to eculizumab across the EP 888 patent family.

Key legal principles
Doctrines and rules cited in the reasoning.
Provisional measures require sufficient certainty of patent validity, not merely the court's own viewCourt must consider the likelihood of EPO opposition/TBA outcome when assessing validityPatent claims interpreted from the skilled person's perspective, considering purposeValidity doubt from consistent adverse TBA history defeats a PI application

Browse other cases on this principle.

Claim construction notes

Identical to UPC_CFI_123/2024: the court construed EP 3 167 888 claims but found it could not be sufficiently certain of validity given the TBA's repeated holdings that SEQ ID NO:4 includes the signal peptide sequence and its refusal to allow correction.